J-GLOBAL ID:201901001033762161   Update date: Dec. 19, 2022

Miki Hirokazu

Miki Hirokazu
Affiliation and department:
Research theme for competitive and other funds  (3):
  • 2017 - 2020 新規抗骨髄腫薬を用いたTh1様γδT細胞の誘導法とその抗骨髄腫活性の増強法の開発
  • 2015 - 2017 Effective expansion of Th1-like gdT cells and anti-myeloma effects
  • 2013 - 2015 Targeting myeloma progenitors by ex vivo-expanded gamma delta T cell
Papers (24):
Books (2):
  • アミロイド原性light chainの脾臓での産生 ALアミロイドーシス,多発性骨髄腫の類縁疾患
    Iyaku Journal Co., Ltd. 2014
  • 多発性骨髄腫に対する合併症の治療(腎,骨,感染症)
Lectures and oral presentations  (106):
  • 輸血後7日目にIgG抗E抗体を酵素法にて強く検出した一症例
    (第45回中四国支部医学検査学会 2121)
  • Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy
    (17th International Myeloma Workshop 2019)
  • ゲノムワイド関連解析を用いたテイコプラニン・バンコマイシン投与による皮疹発現および血中濃度関連遺伝子座の同定
    (日本薬学会 第139年会 2019)
  • Peri-implantitis and the role of Febuxostat in osteoclast differentiation.
    (AEEDC Dubai World Orthodontic Conference 2019)
  • 多発小結節影を認めたHIV陽性ニューモシスチス肺炎の1例
    (第119回日本内科学会四国地方会 2018)
Awards (3):
  • 2017/06/17 - Australian and New Zealand Bone and Mineral Society ANZBMS Plenary Poster Award. Osteoclasts utilize TRAIL for their NF-B activation, but TAK1 inhibition resumes TRAIL-induced apoptosis in osteoclasts.
  • 2016/07/21 - Japanese Society for Bone and Mineral Research 第34回日本骨代謝学会学術集会・第3回アジア太平洋骨代謝学会議,Young investigator award. 破骨細胞はTAK1の発現誘導を介しアポトーシスを抑制しTRAILにより成熟活性化される
  • 2013/10 - The American Society for Bone and Mineral Research Plenary poster & Young Investigator Travel Award 5. Potent induction of bone formation in myeloma bone lesions by the cathepsin K inhibitor KK1-300-01 in combinat ion with the proteasome inhibitor bortezomib.
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page